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Abstract
Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), MET, and ROS1, is approved for treatment
of patients with ALK-positive or ROS1-positive advanced non-small-cell lung cancer (NSCLC). However, ALK rearrangements are also implicated in other malignancies, including anaplastic large-cell
lymphoma and inflammatory myofibroblastic tumors (IMTs). In this ongoing, multicenter, single-arm,

Funding information
Pfizer Inc

open-label phase 1b study (PROFILE 1013; NCT01121588), patients with ALK-positive advanced
malignancies other than NSCLC were to receive a starting dose of crizotinib 250 mg twice daily. Primary endpoints were safety and objective responses based on Response Evaluation Criteria in Solid
Tumors version 1.1 or National Cancer Institute International Response Criteria. Forty-four patients
were enrolled (lymphoma, n 5 18; IMT, n 5 9; other tumors, n 5 17). The objective response rate was
53% (95% confidence interval [CI], 28–77) for lymphoma, with 8 complete responses (CRs) and 1 partial response (PR); 67% (95% CI, 30–93) for IMTs, with 1 CR and 5 PRs; and 12% (95% CI, 2–36) for
other tumors, with 2 PRs in patients affected by colon carcinoma and medullary thyroid cancer, respectively. The median duration of treatment was almost 3 years for patients with lymphoma and IMTs,
with 2-year progression-free survival of 63% and 67%, respectively. The most common treatmentrelated adverse events were diarrhea (45.5%) and vision disorders (45.5%), mostly grade 1. These findings indicate strong and durable activity of crizotinib in ALK-positive lymphomas and IMTs. The safety
profile was consistent with the known safety profile of crizotinib even with long-term treatment.

*Carlo Gambacorti-Passerini and Tae Min Kim contributed equally to the lead
authorship of this article.
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 ALK gene translocation or inversion events (e.g., nucleophosmin

1 | INTRODUCTION

[NPM]-ALK fusion) as determined by fluorescence in situ hybridizaActivating mutations or translocations of the anaplastic lymphoma

tion (FISH), reverse transcriptase (RT)–polymerase chain reaction

kinase (ALK) oncogene have been recurrently identified in several can-

(PCR) or sequencing, or immunohistochemistry (in the case of ALCL)

cer types, including non-small-cell lung cancer (NSCLC), anaplastic

 ALK-activating point mutations determined by direct sequencing of

large-cell lymphoma (ALCL), inflammatory myofibroblastic tumors
(IMTs), and neuroblastoma.1–3 Activation of the ALK gene usually
occurs through chromosomal rearrangement, resulting in the placement
of one of several different 5ʹ fusion partners and their associated pro-

the ALK gene locus
 ALK amplification events (defined as ALK/CEP2 ratio of 5 in 15%
of evaluated cells by FISH or as >7 copies by quantitative PCR or
array comparative genomic hybridization).

moter regions upstream of the ALK kinase domain. ALK point mutations and possibly overexpression of ALK can also lead to activation of

Local ALK testing results were reviewed by the Sponsor to confirm eli-

ALK signaling in human tumors.4–6

gibility. Solid tumors had to be measurable per Response Evaluation

ALCL is a rare form of non-Hodgkin lymphoma (NHL), usually con-

Criteria in Solid Tumors (RECIST) version 1.1 and lymphomas had to be

sisting of large neoplastic cells with abundant cytoplasm and pleomorphic

measurable per the National Cancer Institute (NCI) International

nuclei, with a translocation involving the ALK gene, and expression of

Response Criteria for NHL. Patients with mutations or amplifications

ALK protein and CD30. It accounts for 3% of adult and 10%–15% of

involving c-MET, who were receiving concurrent treatment on another

pediatric NHL cases.7–9 ALCL may be effectively treated using intensive

clinical trial, or who had received prior therapy specifically directed

chemotherapy regimens (e.g. cyclophosphamide, doxorubicin, vincristine,

against ALK, were excluded.

and prednisone [CHOP])10,11 but at the cost of early and long-term toxicities.8,12 In addition, if relapse occurs after first-line treatment, ALCL has

2.2 | Trial design and treatment

a poor prognosis and tends to follow a very aggressive clinical course.13
IMTs are a rare type of mesenchymal neoplasm composed of a
variable mixture of myofibroblasts and inflammatory infiltrates that can
occur throughout the body, predominantly in the mesentery, retroperitoneum, and pelvis. ALK rearrangements have been implicated in giving
rise to oncogenic fusion proteins in 50% of IMTs.

14–18

In addition,

activating ALK mutations are found in about 7%–9% of cases of neuroblastoma, a childhood cancer of the developing nervous system.19,20
Single-agent clinical protocols facilitate rapid enrollment of molecularly profiled patients with genetic alterations linked to targeted thera-

This ongoing, multicenter, open-label, single-arm exploratory phase 1b
study (PROFILE 1013; ClinicalTrials.gov identifier: NCT01121588)25
enrolled patients with advanced malignancies (NHL, IMT, and solid
tumors) harboring a translocation, inversion, mutation, or amplification
event involving the ALK gene locus. Crizotinib, at a starting dose of
250 mg twice daily, was to be orally administered on a continuous dosing
schedule in 21-day cycles to facilitate scheduling of visits and assessments. Patients were permitted to continue treatment with crizotinib if
there was evidence of clinical benefit in the opinion of the investigators.

pies, and early signs of clinical activity in such trials provide
opportunities for detection of new indications using a patient-sparing

2.3 | Trial assessments

design that could lead to subsequent confirmatory trials.21

Patients were to be screened before receiving crizotinib. Subsequent vis-

Crizotinib is a potent, orally administered, small-molecule tyrosine

its were to be scheduled for days 1 and 15 of cycle 1 and then day 1 of all

kinase inhibitor of ALK, MET, and ROS1 receptor tyrosine kinases.22,23

following treatment cycles, with a final visit at the end of treatment. After

Currently, crizotinib has received marketing authorization approvals

a protocol amendment (August 2015), a reduced visit frequency sched-

globally for the treatment of ALK-positive advanced NSCLC in over 90

ule (visits on day 1 of every 6 cycles) was to be followed for ongoing

countries. In 2016, crizotinib was also approved in the United States

patients. Assessments of adverse events (AEs), laboratory safety (hema-

and European Union for the treatment of patients with advanced

tology, chemistry, and coagulation [cycle 1 only]), physical examinations,

NSCLC whose tumors are ROS1-positive.24

and electrocardiograms (cycles 1 and 2 only) were to be performed at

Here, we report the results of the PROFILE 1013 study that eval-

each visit. Safety assessments included collection of AEs, serious AEs

uated the safety and antitumor activity of single-agent, oral crizotinib

(SAEs), vital signs, physical examinations, 12-lead electrocardiograms,

among patients with advanced ALCL, IMT, or other advanced ALK-

laboratory assessments (including pregnancy tests), ophthalmologic

positive malignancies different from NSCLC.

examinations, and documentation of concomitant treatments. On-study
tumor assessments were to be performed at the beginning of cycle 3 and

2 | METHODS

every other cycle up to and including cycle 10. After cycle 10, tumor
assessments were to be performed every 12 weeks, reduced to every 24

2.1 | Patients
Patients aged 15 years with Eastern Cooperative Oncology Group performance status of 0–3 and histologically or cytologically proven diagnosis of ALCL, IMT, or other advanced malignancy (excluding NSCLC) for

weeks from cycle 26 and to every 52 weeks from cycle 52. Tumor
assessments were reviewed by the investigators at study sites.

2.4 | Endpoints

which no standard therapy is available were eligible if they were positive

The primary endpoints were objective response rate (ORR) based on

during local ALK testing with validated methods at study sites for either:

RECIST v1.1 or the NCI International Response Criteria, the type,
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incidence, severity, seriousness, and relationship to study medications

patient was still on treatment and relapse-free at the data cutoff (at

of AEs, and laboratory abnormalities. Secondary endpoints included

cycle 74), after more than 4 years on crizotinib. Patients in the lym-

progression-free survival (PFS), overall survival (OS) at 6 months and 1

phoma group had an ORR of 52.9% (95% CI, 27.8–77.0). This com-

and 2 years, OS, and duration of response (DOR).

prised 8 patients (47.1%) who experienced a complete response (CR)
and 1 patient (5.9%) with a partial response (PR). Median DOR was 2.6

2.5 | Trial oversight
PROFILE 1013 was designed by Pfizer and conducted in collaboration
with the principal investigators (see Supporting Information). All
patients provided written informed consent before enrollment. The
institutional review board or independent ethics committee at each
participating center approved the protocol and amendments, which
complied with the International Ethical Guidelines for Biomedical
Research Involving Human Subjects, Good Clinical Practice guidelines,
the Declaration of Helsinki, and local laws.

2.6 | Statistical analysis

years with all but 1 patient still in response or ongoing at the time of
data cutoff (Supporting Information Figure S1). In addition, 3 patients
(17.6%) had stable disease (SD), including one lasting over 3.5 years
and ongoing at data cutoff in a patient with diffuse large B-cell lymphoma (DLBCL). Median PFS had not been reached (Figure 1) because
of the small number of events (33%) and the high percentage of
patients with lymphoma still in follow-up for progression (44.4%). PFS
at 2 years was 63.0% (95% CI, 35.3–81.4). Of note, all responding
patients who progressed/relapsed did so within the initial 90 days of
treatment and no further progressions/relapses were noted thereafter.
Median OS was also not reached as OS data were immature, with
72.2% of patients with lymphoma still alive at the cutoff (Figure 2).

The sample size for this study was determined empirically based on

One patient underwent a cord stem cell transplant approximately

expected small numbers of patients in the population of interest, and it

4 months after starting crizotinib treatment and was subsequently cen-

was anticipated that approximately 40 patients would be enrolled. The

sored for evaluation of tumor response-related endpoints. The patient

study population for all analyses (except tumor response-related end-

resumed crizotinib after the transplant and was still ongoing and

points) included patients enrolled in the study who received at least

disease-free at the data cutoff, after more than 4 years on crizotinib.

one dose of crizotinib. For response-related endpoints, enrolled
patients who received at least one dose of crizotinib also had to have
an adequate baseline tumor assessment.

3.2.2 | IMT group
All patients with IMT were evaluable for response (Table 2). Patients in

Descriptive statistics were used to summarize patient characteris-

the IMT group had an ORR of 66.7% (95% CI, 29.9–92.5), which com-

tics, treatment administration, antitumor activity, and safety. The ORR

prised 1 CR and 5 PRs. Three patients are still in response, with

was summarized with the corresponding exact 2-sided 95% confidence

responses lasting over 2 years, and these patients remain in follow-up

interval (CI) calculated using a method based on the F distribution. Sec-

(Supporting Information Figure S1). In addition, 3 patients (33.3%) had

ondary time-to-event endpoints were summarized using Kaplan-Meier

SD. Median PFS was not reached in the IMT group (Figure 1) because

methods. The data cutoff date was March 4, 2016. Data were summar-

of the small number of events (33%) and 55.6% of patients with IMT

ized for the overall patient population, as well as separately for antitu-

who remain in follow-up for progression. PFS at 2 years was 66.7%

mor activity in the ALCL, IMT, and “other tumors” patient groups.

(95% CI, 28.2–87.8). In addition, median OS was not reached as 66.7%
of patients with IMT were alive at the data cutoff (Figure 2).

3 | RESULTS
3.1 | Patients

3.2.3 | “Other tumors” group
All patients in the “other tumors” group were evaluable for response
(Table 2), and the ORR was 11.8% (95% CI, 1.5–36.4). This comprised

From March 2011 through October 2013, a total of 44 patients were

2 of 17 patients (11.8%) ALK-positive for rearrangement on FISH who

enrolled in the study (lymphoma, n 5 18; IMT, n 5 9; and other tumors,

achieved a PR (one with mucinous carcinoma of the colon [response

n 5 17). Demographic characteristics are shown in Table 1, and

duration, 103.3 weeks] and one with medullary thyroid cancer

patients’ diagnoses in the other tumors group are shown in Supporting

[response duration, 16.1 weeks]). In addition, 4 patients (23.5%) had

Information Table S1. All enrolled patients were either white or Asian

SD, of which 1 patient with advanced neuroblastoma harboring ALK

in nearly equal proportions (Japanese, Korean, or Chinese).

F1174L mutation had SD lasting 19 months. Among patients with
other tumors, median PFS was 1.3 months (95% CI, 1.1–3.9) (Figure 1),

3.2 | Antitumor activity

PFS at 2 years was 6.3% (95% CI, 0.4–24.7), and median OS was

3.2.1 | Lymphoma group

8.3 months (95% CI, 2.2–16.9) (Figure 2).

In the lymphoma group, 17 of 18 patients were evaluable for response
(Table 2), as 1 patient was retrospectively found not to have measura-

3.3 | Safety

ble disease. The patient was followed for antitumor activity based on

At the time of data cutoff, the duration of crizotinib treatment ranged

positive RT-PCR status for NPM-ALK, which predicts a poor progno-

from 0.1 to 249.3 weeks (57 months) across all patients, with median

sis,26 and became RT-PCR negative within 4 months of treatment; this

treatment durations of 35 months, 33 months, and 1 month for the

610

A JH

|

T AB LE 1

GAMBACORTI-PASSERINI

ET AL.

Patient baseline characteristics and demographics
Lymphomas
(n 5 18)

IMT
(n 5 9)

Other tumors
(n 5 17)

Total
(N 5 44)

Sex
Male

12 (66.7)

5 (55.6)

8 (47.1)

25 (56.8)

Age, years
Median
Range

25.0
15–37

32.0
16–73

53.0
26–73

32.0
15–73

ECOG performance status
0
1
2
3

4
7
5
2

(22.2)
(38.9)
(27.8)
(11.1)

4
4
1
0

(44.4)
(44.4)
(11.1)
(0.0)

5
9
2
1

(29.4)
(52.9)
(11.8)
(5.9)

13 (29.5)
20 (45.5)
8 (18.2)
3 (6.8)

Race
White
Asian
Japanese
Korean
Chinese

12 (66.7)
6 (33.3)
2 (11.1)
2 (11.1)
2 (11.1)

4
5
1
1
3

(44.4)
(55.6)
(11.1)
(11.1)
(33.3)

7 (41.2)
10 (58.8)
2 (11.8)
4 (23.5)
4 (23.5)

23 (52.3)
21 (47.7)
5 (11.4)
7 (15.9)
9 (20.5)

Smoking classification
Never
Former
Current

10 (55.6)
5 (27.8)
3 (16.7)

6 (66.7)
3 (33.3)
0 (0.0)

14 (82.4)
2 (11.8)
1 (5.9)

30 (68.2)
10 (22.7)
4 (9.1)

0 (0.0)
18 (100)

6 (66.7)
3 (33.3)

1 (5.9)
16 (94.1)

7 (15.9)
37 (84.1)

2
6
5
3
1
1
0

2
1
0
0
0
0
0

3
4
3
3
0
2
1

7 (15.9)
11 (25.0)
8 (18.2)
6 (13.6)
1 (2.3)
3 (6.8)
1 (2.3)

Prior systemic therapy
No
Yes
No. of regimens
1
2
3
4
5
6
7

(11.1)
(33.3)
(27.8)
(16.7)
(5.6)
(5.6)
(0.0)

(22.2)
(11.1)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)

(17.6)
(23.5)
(17.6)
(17.6)
(0.0)
(11.8)
(5.9)

Data are presented as n (%) unless otherwise noted.
ECOG, Eastern Cooperative Oncology Group; IMT, inflammatory myofibroblastic tumor.

lymphoma, IMT, and “other tumors groups”, respectively; a total of 16

indicated that this event was aspiration pneumonia and not related to

of 44 patients (36.4%) were still receiving crizotinib treatment. At least

the study drug.

one AE of any cause was reported in 43 of 44 patients (97.7%)

Permanent discontinuation of crizotinib associated with TRAEs

(Supporting Information Table S2), and treatment-related AEs (TRAEs)

occurred in the 2 patients with cerebral infarction (2.3%) and interstitial

occurred in a total of 39 patients (88.6%) (Table 3). Mild-to-moderate

lung disease (2.3%). Disease progression led to permanent discontinua-

diarrhea and vision disorder were the most common TRAEs reported

tion from treatment in 50% of patients.

(both 45.5%), most of which were grade 1.

Overall, 21 patients died during the study. Seventeen patients died

Overall, 9 patients (20.5%) experienced an SAE considered to be

because of disease progression, 1 patient died from interstitial lung dis-

related to crizotinib treatment (Table 3). The most common SAE con-

ease/aspiration pneumonia, and 1 patient died because of cerebral infarc-

sidered possibly related to treatment was grade 4 blood creatine phos-

tion (the latter 2 as previously described). During long-term follow-up, 1

phokinase increase reported in 3 patients (6.8%), all in clinical response

patient died because of small bowel obstruction and hernia complication

and concurrent with strenuous physical activity that is known to cause

(13 months after treatment discontinuation) and 1 patient’s cause of death

brisk elevations of creatine phosphokinase levels.27

(10 months after treatment discontinuation) remained unknown.

Grade 5 AEs considered by the investigator as related to treatment
occurred in 2 patients: cerebral infarction in a patient with unknown

4 | DISCUSSION

primary tumor and multiple brain metastases, concurrent with disease
progression, and interstitial lung disease in a patient with nasopharyn-

Crizotinib has been shown to be superior to standard chemotherapy in

geal carcinoma. Subsequent review by an independent radiology com-

previously treated and untreated patients with ALK-positive advanced

mittee, consisting of a pulmonologist, radiologist, and oncologist,

NSCLC28,29 and has previously been shown to have therapeutic activity

GAMBACORTI-PASSERINI

TA BL E 2

A JH

ET AL.

|

611

Patient response to crizotinib treatment
Lymphoma
(n 5 17)

IMT
(n 5 9)

Other
(n 5 17)

Best overall response, n (%)
Complete response
Partial response
Stable disease
Objective progression
Early death
Indeterminate

8
1
3
3
1
1

1
5
3
0
0
0

0
2
4
7
3
1

Objective response rate, %
95% CI

52.9
27.8–77.0

(47.1)
(5.9)
(17.6)
(17.6)
(5.9)
(5.9)

(11.1)
(55.6)
(33.3)
(0.0)
(0.0)
(0.0)

(0.0)
(11.8)
(23.5)
(41.2)
(17.6)
(5.9)

66.7
29.9–92.5

11.8
1.5–36.4

Duration of response, weeks
Median
135.9
Range
6.0–205.9

74.1
29.6–138.3

59.7
16.1–103.3

Stable disease duration, n (%)a
<3 months
2 (66.7)
3–<6 months
0 (0.0)
6–<9 months
0 (0.0)
9–<12 months
0 (0.0)
12 months
1 (33.3)

0
1
0
0
2

0
2
1
0
1

(0.0)
(33.3)
(0.0)
(0.0)
(66.7)

(0.0)
(50.0)
(25.0)
(0.0)
(25.0)

a

Percentages based on the number of patients with stable disease.
CI, confidence interval; IMT, inflammatory myofibroblastic tumor.

Overall survival.
IMT, inflammatory myofibroblastic tumor

FIGURE 2

Our study cohorts show notable and durable antitumor activity of
crizotinib as monotherapy for patients with advanced, relapsed or
refractory ALK-positive ALCL and ALK-positive IMT, together with a

Treatment-related AEs and SAEs in patients treated with
crizotinib (N 5 44)

T AB LE 3

Maximum CTCAE

in relapsed and resistant ALK-positive lymphomas.30–34 These findings,

Event, n (%)

together with previous studies, encourage the use of crizotinib as a

Any AE

potential treatment option in ALK-positive lymphoma, although some

a

AEs in 10% of patients
Diarrhea
Vision disorderb
Nausea
Elevated transaminasesb
Vomiting
Neutropeniab
Edemab
Abdominal painb
Leukopeniab
Fatigue
Headache
Constipation
CPK increased

lack long-term follow-up data.
Patients with relapsed ALK-positive lymphoma generally have a poor
prognosis and, presently, there is no consensus on the optimal chemotherapy combination for relapsed ALCL.7,8 Brentuximab vedotin induced objective responses in a majority (86%) of 58 patients (57% CR, 29% PR) with
recurrent systemic ALCL (median DOR and PFS of 12.6 and 13.3 months,
respectively)35 and has been approved for the treatment of systemic ALCL
after failure of 1 prior multiagent chemotherapy regimen. However,
brentuximab vedotin is unlikely to represent a long-term treatment for
advanced ALCL because of its side effects (incremental neurotoxicity), par-

Any grade Grade 3

Grade 4 Grade 5

39 (88.6)

16 (36.4) 6 (13.6)

2 (4.5)

20 (45.5)
20 (45.5)
17 (38.6)
15 (34.1)
15 (34.1)
14 (31.8)
11 (25.0)
10 (22.7)
9 (20.5)
7 (15.9)
7 (15.9)
6 (13.6)
5 (11.4)

0
0
2
3
3
8
0
1
1
2
0
0
1

0
0
0
0
0
0
0
0
0
0
0
0
0

Any grade

Grade 3

Grade 4

Grade 5

9
3
1
1
1
1
1

1
0
0
0
1
0
1

4
3
1
0
0
0
0

2
0
0
1
0
1
0

(0.0)
(0.0)
(4.5)
(6.8)
(6.8)
(18.2)
(0.0)
(2.3)
(2.3)
(4.5)
(0.0)
(0.0)
(2.3)

0
0
0
0
0
2
0
0
0
0
0
0
3

(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(4.5)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(6.8)

(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)

enteral route of administration, and general use as a bridge therapy.
Maximum CTCAE
Any SAEa
CPK increased
Cardiac failureb
Cerebral infarction
Deep vein thrombosis
Interstitial lung diseaseb
Myocardial ischemia
a

Progression-free survival.
IMT, inflammatory myofibroblastic tumor

(2.3)
(0.0)
(0.0)
(0.0)
(2.3)c
(0.0)
(2.3)c

(9.1)
(6.8)
(2.3)c
(0.0)
(0.0)
(0.0)
(0.0)

(4.5)
(0.0)
(0.0)
(2.3)
(0.0)
(2.3)
(0.0)

Patients are counted once under the highest CTCAE grade.
This item comprised a cluster of AEs that may represent similar clinical
symptoms or syndromes, listed in Supporting Information Table S3.
c
Deep vein thrombosis (grade 3; n 5 1) was concurrent with a course of corticosteroids; myocardial ischemia (grade 3) and cardiac failure (grade 4) occurred
in the same patient, who had preexisting hypertension and coronary artery disease. These grade 3 SAEs were considered possibly treatment-related by the
investigator; however, their relationship to concomitant medications, coexisting medical conditions, or tumor progression could not be clearly established.
AE, adverse event; CPK, creatine phosphokinase; CTCAE, Common Terminology Criteria for Adverse Events; SAE, serious adverse event.
b

FIGURE 1

(20.5)
(6.8)
(2.3)
(2.3)
(2.3)
(2.3)
(2.3)
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favorable safety profile that was consistent over long-term treatment.

groups in this study (35 and 33 months, respectively). The treatment

This study suggests that crizotinib may also offer a potential long-term

durations (up to 57 months) in this study are currently the longest

treatment option, with an OS at 2 years similar to that reported with

reported in the literature in adult patients and therefore provide new

first-line CHOP chemotherapy in patients with ALK-positive ALCL36

information about the long-term safety of crizotinib.

and a PFS at 2 years that exceeds 60% in ALK-positive ALCL. Abrupt

Crizotinib was generally well tolerated; the safety profile observed

relapses of ALK-positive lymphoma following crizotinib discontinuation

was similar to that reported previously with crizotinib, and no new

have been reported, and it has been suggested that caution must be

safety signals were identified.28,29,45 Limitations of this study include

exercised when interrupting treatment in patients with ALK-positive

its single-arm, open-label design, small patient population, and the het-

32

erogeneity of the patients’ tumors.

lymphomas, since ALCL may recur rapidly.

One patient in this study had ALK-positive DLBCL and experi-

In conclusion, this study indicated strong and durable activity of

enced SD lasting almost 4 years, a clinically meaningful response for

crizotinib in ALK-positive lymphomas and IMTs. Treatment duration

this rare form of lymphoma that exhibits a more aggressive clinical

was much longer than usual treatment in patients with NSCLC, and the

37

safety profile was consistent with the known safety profile of crizoti-

course and worse prognosis than typical DLBCL.

Sustained and durable responses to crizotinib in lymphoma were

nib, even with long-term treatment.

observed in another study performed in 26 pediatric patients with
relapsed or refractory ALK-positive ALCL, which represent an update of
a previous publication.33 Although a high response rate of 90% was
observed in the Children’s Oncology Group study, one-half of patients
ultimately received stem cell transplantation,34 thus rendering the evaluation of the long-term effects of crizotinib in this population problematic.
In PROFILE 1013, this was not a confounding factor as only 1 responder
underwent bone marrow transplantation and was censored at that time.
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Previous reports have shown that crizotinib has antitumor activity in
patients with unresectable ALK-positive IMTs34 as well as in those with
refractory ALK-positive IMT.33,38 A case report of a patient with ALK-
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positive IMT documented complete radiographic remission 2 years after
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initiating crizotinib treatment.39 The results of our study indicate a
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marked antitumor activity, with nearly two-thirds of objective responses
lasting >2 years and a PFS at 2 years of 67%. The durable responses
observed in this small set of patients further support the National Comprehensive Cancer Network’s recommendation of crizotinib as a treatment for IMTs with an ALK rearrangement40 and suggest that ALK
testing should be routinely performed in all patients with IMT.
In contrast, a low level of response was observed in the “other
tumors” group, which included a variety of ALK-positive tumors. Potential reasons for lack of clinical activity include differences in ALK signaling events in different tumor types (i.e., “early” vs “late” events during
tumor progression), differing tumor types, and genetics of the tumor
cell, which may affect the response to ALK tyrosine kinase inhibitors.41
In addition, point mutations permitted in this study, for example
F1174L and F1245C (common ALK-activating mutations seen in neuroblastoma), have been shown to confer resistance to crizotinib in neuroblastoma and other cancers.33,42,43 MYCN overexpression has also
been associated with resistance to ALK inhibitors.44 However, in this
subgroup, 1 patient with mucinous carcinoma of the colon achieved a
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long-lasting response of almost 2 years, 1 patient with medullary thyroid carcinoma also responded to crizotinib with a response duration of
4 months, and 1 patient with neuroblastoma had SD for 19 months,
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